Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Filing Details

Accession Number:
0001012975-14-000084
Form Type:
4
Zero Holdings:
No
Publication Time:
2014-02-13 14:27:40
Reporting Period:
2014-02-11
Filing Date:
2014-02-13
Accepted Time:
2014-02-13 14:27:40
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1485003 Eleven Biotherapeutics Inc. EBIO Pharmaceutical Preparations (2834) 252025616
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1180428 J Mark Levin 29 Newbury Street, 3Rd Floor
Boston MA 02116
Yes No Yes No
1192595 I Robert Tepper 29 Newbury Street, 3Rd Floor
Boston MA 02116
No No Yes No
1192603 P Kevin Starr 29 Newbury Street, 3Rd Floor
Boston MA 02116
No No Yes No
1408591 Third Rock Ventures Lp 29 Newbury Street, 3Rd Floor
Boston MA 02116
No No Yes No
1578973 Trv Gp, Llc 29 Newbury Street, 3Rd Floor
Boston MA 02116
No No Yes No
1578976 Third Rock Ventures Gp, L.p. 29 Newbury Street, 3Rd Floor
Boston MA 02116
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2014-02-11 3,267,716 $0.00 3,598,424 No 4 C Direct
Common Stock Acquisiton 2014-02-11 481,619 $0.00 4,080,043 No 4 C Direct
Common Stock Acquisiton 2014-02-11 127,077 $0.06 4,207,120 No 4 C Direct
Common Stock Acquisiton 2014-02-11 82,989 $0.00 4,290,109 No 4 C Direct
Common Stock Acquisiton 2014-02-11 551,482 $0.00 4,841,591 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Direct
No 4 C Direct
No 4 C Direct
No 4 C Direct
No 4 P Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Series A Preferred Stock Disposition 2014-02-11 20,750,000 $0.00 3,267,716 $0.00
Common Stock Series B Preferred Stock Disposition 2014-02-11 3,058,281 $0.00 481,619 $0.00
Common Stock Common Stock Warrant (right to purchase) Disposition 2014-02-11 127,077 $0.00 127,077 $0.06
Common Stock Common Stock Warrant (right to purchase) Disposition 2014-02-11 82,989 $0.00 82,989 $0.06
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Direct
0 No 4 C Direct
0 No 4 C Direct
0 No 4 C Direct
Footnotes
  1. The Series A Preferred Stock converted automatically into Common Stock on a 6.350 for-one basis upon the closing of the initial public offering of Eleven Biotherapeutics, Inc. (the "Issuer") without payment of additional consideration and had no expiration date.
  2. The shares are directly held by Third Rock Ventures, L.P. ("TRV"). The general partner of TRV is Third Rock Ventures GP, L.P. ("TRV GP"). The general partner of TRV GP is TRV GP, LLC ("TRV GP LLC"). The individual managers of TRV GP, LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper") and, as such, each of TRV GP and TRV GP LLC, Levin, Starr and Tepper exercises shared voting and investment power over the shares held of record by TRV. Each of the filing persons disclaims beneficial ownership of the shares except to the extent of their pecuniary interest therein, if any.
  3. The Series B Preferred Stock converted automatically into Common Stock on a 6.350 for-one basis upon the closing of the initial public offering of the Issuer without payment of additional consideration and had no expiration date.
  4. The Warrant to purchase Common Stock was exercised automatically upon the closing of the Issuer's initial public offering and had an expiration date of June 28, 2018.
  5. The Warrant to purchase Common Stock was exercised automatically upon the closing of the Issuer's initial public offering and had an expiration date of December 4, 2018.